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Abstract
Physical activity is a known modiﬁable lifestyle means for reducing postmenopausal breast cancer
risk, but the biologic mechanisms arenot wellunderstood.Metabolic factors maybe involved. Inthis
study, we aimed to determine the effects of exercise on insulin resistance (IR) indicators, IGF1, and
adipokines in postmenopausal women. The Alberta Physical Activity and Breast Cancer Prevention
Trialwasatwo-armedrandomizedcontrolledtrialinpostmenopausal,inactive,cancer-freewomen.A
year-longaerobicexerciseinterventionof225 min/week(nZ160)wascomparedwithacontrolgroup
asked to maintain usual activity levels (nZ160). Baseline, 6- and 12-month serum levels of insulin,
glucose,IGF1,IGF-bindingprotein3(IGFBP3),adiponectin,andleptinwereassayed,andafterdata
collection, homeostasis model assessment of IR (HOMA-IR) scores were calculated. Intention-
to-treat analyses were performed using linear mixed models. The treatment effect ratio (TER) of
exercisers to controls was calculated. Data were available on 308 (96.3%) women at 6 months and
310 (96.9%) women at 12 months. Across the study period, statistically signiﬁcant reductions in
insulin (TERZ0.87, 95% conﬁdence interval (95% CI)Z0.81–0.93), HOMA-IR (TERZ0.86, 95%
CIZ0.80–0.93),andleptin(TERZ0.82,95%CIZ0.78–0.87),andanincreaseintheadiponectin/leptin
ratio (TERZ1.21, 95% CIZ1.13–1.28) were observed in the exercise group compared with
the control group. No signiﬁcant differences were observed for glucose, IGF1, IGFBP3,
adiponectin or the IGF1/IGFBP3 ratio. Previously inactive postmenopausal women who engaged
in a moderate-to-vigorous intensity exercise program experienced changes in insulin, HOMA-IR,
leptin, and adiponectin/leptin that might decrease the risk for postmenopausal breast cancer.
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Physical activity reduces the risk of postmenopausal
breast cancer (Monninkhof et al. 2007, World Cancer
Research Fund and the American Institute for Cancer
Research 2007, Friedenreich & Cust 2008, Lynch et al.
2011), but the biologic mechanisms underlying this
association are not well understood. Insulin (Osborne
et al. 1976, Chappell et al. 2001) insulin-like growth
factor 1 (IGF1 and its binding proteins; Yu & Rohan
2000, Lann & LeRoith 2008) leptin (Catalano et al.
2003, Geisler et al. 2007, Cirillo et al. 2008), and
adiponectin (Brakenhielm et al. 2004, Dieudonne et al.
2006, Arditi et al. 2007) are metabolic factors
hypothesized to mediate the association between
physical activity and postmenopausal breast cancer
risk (Neilson et al. 2009).
Differing levels of evidence support roles for these
proposed biomarkers in breast cancer, but the greatest
pool of epidemiologic data in postmenopausal women
exists for insulin (Gunter et al. 2009, Kabat et al. 2009,
Neilson et al. 2009) and IGF1 and its binding proteins
(Key et al. 2010). The link between insulin and breast
cancer is now sufﬁciently convincing that metformin, a
pharmacologic agent that improves insulin sensitivity,
is being considered for breast cancer prevention and
treatment (Gonzalez-Angulo & Meric-Bernstam 2010)
with clinical trials underway (Cazzaniga et al. 2009,
Goodwin et al. 2009). An association between high
circulating IGF1 and breast cancer risk has been
demonstrated fairly consistently among premenopau-
sal, but not postmenopausal, women (Fletcher et al.
2005) and associations with IGF-binding protein 3
(IGFBP3) have been inconsistent (Renehan et al.
2006). Nevertheless, a recent pooled analysis found a
signiﬁcantly increased risk of breast cancer with
elevated IGF1 and IGFBP3 in postmenopausal
women (Key et al. 2010).
Leptin and adiponectin are adipokines that relate
strongly to obesity and insulin resistance (IR; Pittas
et al. 2004, Dyck et al. 2006) but their roles in breast
cancer are unclear. While it is biologically plausible
that leptin increases postmenopausal breast cancer risk,
epidemiological ﬁndings have been inconsistent
(Neilson et al. 2009, Wu et al. 2009, Maccio et al.
2010). In contrast, most studies in postmenopausal
women have shown signiﬁcant inverse associations
between adiponectin and breast cancer risk (Neilson
et al. 2009). Emerging research suggests that the ratio
of adiponectin:leptin (A/L or conversely, L/A)
provides a surrogate measure of IR (Finucane et al.
2009), and perhaps also acts as an indicator of
postmenopausal breast cancer risk, which may be
more sensitive than either marker on its own (Cleary
et al. 2009, Jarde et al. 2009).
Since all of these proposed biomarkers are related
to IR and obesity, we hypothesized that their levels
could be modiﬁed with sustained physical activity.
Only a few studies have addressed this question
previously via randomized controlled trials (RCTs)
on postmenopausal women (Neilson et al. 2009),
including one RCT that focused on breast cancer
(Frank et al. 2005). A need for additional tightly con-
trolled, long-term intervention trials to examine the
impact of exercise on proposed biomarkers for breast
cancer risk has been widely recognized (McTiernan
et al. 1999, Friedenreich 2001, IARC Working Group
2002, Kushi et al. 2006, Physical Activity Guidelines
Advisory Committee 2008). In response to this
recognized need for more research, the Alberta
Physical Activity and Breast Cancer Prevention
(ALPHA) Trial was a 12-month exercise intervention
trial designed to improve the understanding of the
biologic mechanisms mediating the association
between physical activity and postmenopausal breast
cancer risk. We previously reported that the interven-
tion signiﬁcantly decreased adiposity (Friedenreich
et al. 2010b) and circulating estradiol and increased
sex hormone-binding globulin (Friedenreich et al.
2010a), which were primary outcomes of the trial.
Here, we report on metabolic factors as secondary
outcomes, namely, insulin, glucose, homeostasis
model assessment of IR (HOMA-IR), IGF1, IGFBP3,
IGF1/IGFBP3 ratio, leptin, adiponectin, and A/L ratio.
Materials and methods
The design and methods for the ALPHA Trial have
been described (Friedenreich et al. 2010a). In brief,
this study was an efﬁcacy trial designed as a two-
centred, two-armed RCT conducted in postmenopausal
women living in Calgary and Edmonton, Alberta,
Canada. The study and protocol were approved by the
Research Ethics Boards at the Alberta Cancer Board
and the Universities of Calgary and Alberta. All
participants provided written informed consent.
Participants and randomization
We recruited women from the general population
through targeted mailings to participants in the Alberta
Breast Screening Program, posters and brochures
distributed to family physicians, and through media
campaigns. Speciﬁc eligibility criteria included: age
50–74 years; postmenopausal; no previous cancer
diagnosis; no major co-morbidities; acceptable heart
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(!90 min/week of exercise or, if 90–120 min/week,
having a VO2max level !34 ml/kg per min); physician
clearance for unrestricted physical activity; normal
fasting levels of glucose, serum cholesterol, TSH,
alanine aminotransferase; body mass index (BMI)
22–40 kg/m
2;non-smoker;!14drinksofalcohol/week;
no medications or exogenous hormones that might
inﬂuence estrogen metabolism; and not currently in a
weight loss program or planning to undertake the one.
A stratiﬁed (on center and BMI), blocked random-
ization was achieved using a random number program
in S-plus written by the study biostatistician (R F B).
Numbered, sealed envelopes were opened by the Study
Coordinator at the time of randomization. Outcome
assessments were blinded to group assignment.
Intervention
The exercise prescription was aerobic exercise for at
least 45 min, 5 days/week for 1 year. At least three
sessions/week were facility-based with on-site exercise
trainers, and the remaining sessions were home-based.
Participants wore heart rate monitors (Polar A3) to
maintain workout intensity at the target of 70–80%
of heart rate reserve. The prescription ramped up over
the ﬁrst 3 months and was maintained for the ﬁnal
9 months. Adherence was monitored through weekly
participant- and trainer-administered exercise logs.
Controls were asked to maintain their inactive lifestyle.
All participants were instructed not to change their
usual diet.
Covariate information
Demographic characteristics, medical and reproduc-
tive history were obtained from a self-administered
baseline questionnaire; all other covariate measures
were taken at baseline and 12 months. Dietary intake
of the previous year was assessed using the National
Cancer Institute’s Diet History Questionnaire pre-
viously adapted for use in Canadian populations
(Csizmadi et al. 2007) and physical activity was
assessed using the past year total physical activity
questionnaire (Friedenreich et al. 2006). Fitness was
assessed using a modiﬁed Balke treadmill protocol
to estimate maximum oxygen consumption (VO2max)
from submaximal exercise intensities. Duplicate
anthropometric measurements were taken using
standardized methods. Total body fat was assessed
using whole body dual X-ray absorptiometry scans
(Friedenreich et al. 2010b). Percent body fat was
calculated as 100%!(fat mass/(fat massClean mass)).
Blood collection and hormone assays
Blood was collected after a minimum 10 h fast at base-
line (60 ml), 6 and 12 months (40 ml), and medications
taken in the past 24 h were recorded. Participants were
asked not to exercise for 24 h pre-blood draw. All blood
sampleswerecollected,processed,andstoredwithin12 h
of collection, thenshipped andstored in K86 8C freezers
untilassay.AnalyseswereconductedbytheReproductive
Endocrine Research Laboratory at the University
of Southern California (FZS), a laboratory with
well-establishedprotocolsandqualitycontrolprocedures.
Eachparticipant’ssamplesfromthethreetimepoints
were included in a single batch, but the order was ran-
domized. Each batch had an equal number of samples
fromexercisersandcontrolswithsimilarrandomization
dates and two pooled quality control samples. The
quality control serum pool consisted of blood drawn
from women who were interested in the study,
postmenopausal, and not taking hormone replacement
therapy, but deemed ineligible after blood draw for
reasons unrelated to the metabolic factors of interest.
Additional repeat blood samples from volunteers were
included to assess within-subject, between-time varia-
bility.Laboratorypersonnelwereblindedtosubjectand
quality control sample identity.
Insulin, IGF1 and IGFBP3 were measured by direct
chemiluminescent immunoassay using the Immulite
Analyzer (Siemens Medical Solutions Diagnostics,
Malvern, PA, USA); intra-assay coefﬁcients of
variation (CV) were 3, 2 and 7%, and inter-assay CV
were 3, 4 and 7% respectively. Glucose was measured
using the oxygen rate method, employing an oxygen
electrode on a Beckman glucose analyzer (Model
DT60II, VitrosSystem,Johnson &Johnson, Rochester,
NY, USA); the intra-assay CV was 8% and the inter-
assayCVwas13%.Asurrogatemeasureofwhole body
insulin sensitivity and b-cell function, HOMA-IR, was
calculated as: fasting glucose (mM)!fasting insulin
(mIU/ml)/22.5 (Hosker et al. 1985, Matthews et al.
1985, Bonora et al. 1989, Levy et al. 1991, Rudenski
et al. 1991, Turner et al. 1993). Leptin and total
adiponectin were measured by RIA (Millipore, St
Charles, MO, USA); intra-assay and inter-assay CV
were 6 and 5%, and 8 and 12% respectively.
Sample size
Sample size calculations were based on the primary
estrogen and adiposity outcomes for which power
R80% was available (Friedenreich et al. 2010a). For
IR outcomes, using the same approach for sample size
estimation as for the primary outcomes, namely the
normal theory formula for comparing means of two
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1986) and S.D. from the Physical Activity for Total
Health trial, (Irwin et al. 2003, McTiernan et al. 2004)
we had power O95% to detect changes of 10–20%.
Statistical analysis
The primary analysis assessed the intervention effect
based on assigned group at randomization regardless of
adherence for participants with complete data at
baseline and end of study (intent-to-treat). Skewness
in these biomarkers was corrected using natural
logarithm transformations. Intervention effects were
evaluated with general linear models considering IR
indicators, IGF1, IGFBP3, leptin, and adiponectin
measures at 6 and 12 months as repeated measures.
Speciﬁcally, we used the following general linear
model:
Yij Zb0 Cb1Xi CgZij C3ij
where, for ith subject, Yij is a log-transformed
biomarker measure at jth time (jZ1 for 6 months and
jZ2 for 12 months), Xi is an indicator variable for the
exercise intervention arm (0 for control and 1 for
exercise intervention), Zij is a vector of adjustment
variables including the baseline biomarker value, time,
and change in the total energy intake, and (3i1, 3i2)i sa
potentially correlated error vector that followed a
bivariate Gaussian distribution with a mean of 0. Of the
parameters b0, b1, and g (associated with the intercept,
exercise intervention, and adjustment variables
respectively), b1 was our main interest, representing
the adjusted difference in the mean log biomarker
measure between the exercise intervention group and
the control group over the two follow-up time points,
adjusting for the baseline biomarker value, time,
and change in the total energy intake. We referred to
the exponential of b1 as the treatment effect ratio
(TER), as it is a ratio of adjusted geometric means of
the biomarker for the exercise intervention group over
the control group.
Secondary analyses examined whether or not the
effect of exercise on the metabolic factors varied by
adherence and body composition change from baseline
to 12 months. Spearman’s rank correlation coefﬁcients
were estimated to relate changes in metabolic factors
to changes in percent body fat in exercisers. We
classiﬁed exercise adherence into three categories pre-
deﬁned by public health guidelines: !150, 150–225,
and O225 min/week (Warburton et al. 2007, Physical
3454  Assessed for eligibility
1840  Did not meet inclusion criteria
798    Refused to participate
274    Other reasons
542   Interested and attended
         information session
19   Ineligible mammogram
14   Failed physician screen
31   Failed blood screen
30   Failed fitness test
31   Ineligible for other reasons
37   Refused to participate
320   Randomized
160   Control group 160   Exercise group
5   Lost to follow-up
        5 Dropped out
154   6 month blood samples
154   12 month blood samples
154   6 month blood samples
154   12 month blood samples
4   Lost to follow-up
       3 Dropped out
       1 Died
Figure 1 Recruitment, randomization, and follow-up of participants in the Alberta Physical Activity and Breast Cancer Prevention
Trial 2003–2006.
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statistical tests were two-sided with a signiﬁcance level
set at 0.05. Statistical analyses were performed using
SAS Software (Version 9.1; SAS Institute, Inc., Cary,
NC, USA).
Results
A total of 3454 women were assessed for eligibility;
320 women were randomized and nine were lost to
follow-up post-randomization. The primary analysis
included 154 exercisers and 154 controls with 6-month
blood samples and 154 exercisers and 156 controls
with 12-month blood samples (Fig. 1). Recruitment
began in May 2003 and was completed in June 2006.
Exercisers and controls were similar at baseline with
respect to age, body composition, and proposed
biomarker concentrations (Table 1). Baseline leptin
concentrations were high relative to normal weight
women (Mahabir et al. 2007) and w80% of women
were overweight or obese (BMIR25).
Adherence to our intervention has been previously
reported (Friedenreichetal.2010a).Inbrief, exercisers
reported a larger 12-month increase in recreational
activity than controls (20.2 vs 3.2 metabolic equivalent
(MET)-hours/week,P!0.001). Sixteencontrols(10%)
reported increasing recreational activity levels by 20
MET-hours/week (equivalent to 200 min/week activity
R6 MET-level (vigorous)) or more. Physical ﬁtness,
measured by VO2max, increased in exercisers versus
controls (3.9 vs 0.7 ml/kg per min, P!0.001).
The main analyses showed an inverse effect of
exercise on insulin, HOMA-IR, and leptin (P!0.001;
Table 2) and a positive effect on the A/L ratio
(PZ0.001).Thegreatestchangesinexercisersoccurred
in the ﬁrst 6 months. Twelve-month percent changes
relative to baseline were K10.3% for insulin, K11.4%
forHOMA-IR,K18.9%forleptin,andC24.9%forthe
A/L ratio. There was no difference between exercisers
and controls across 12 months for changes in glucose,
IGF1, IGFBP3, IGF1/IGFBP3, or adiponectin.
In secondary analyses, exercise duration was consis-
tently associated with monotonic reductions in insulin,
HOMA-IR, and leptin concentrations (Table 3) but
not glucose, IGF1, IGFBP3, IGF1/IGFBP3, or adipo-
nectin (data not shown). The A/L ratio increased with
increasing weekly duration of exercise. The highest
decreases of 16 and 30% were achieved with exercise
O225 min/weekfor HOMA-IR andleptin,respectively,
while the A/L ratio increased by 48% in this subgroup;
also glucose decreased signiﬁcantly (5.4%, PZ0.013).
Nosigniﬁcantchanges(P!0.05)occurredwithexercise
!150 min/week for any proposed biomarker.
Theeffectsoftheinterventiononinsulin,HOMA-IR,
leptin, and the A/L ratio were attenuated after
adjustment for adiposity change (Table 4). Adjustment
for change in total or percent body fat had a greater
impact on TER than changes in body weight or intra-
abdominal fat, with effects becoming non-statistically
signiﬁcantforHOMA-IR(PZ0.073andPZ0.065)and
the A/L ratio (PZ0.207 for both adiposity measures).
Correlations between percent body fat change and
metabolic changes in exercisers (data not shown) were
strongest for leptin (rSZ0.50, P!0.001) and the A/L
ratio (rSZK0.55, P!0.001).
Discussion
This year-long aerobic exercise intervention among
postmenopausal inactive women resulted in reductions
in insulin, HOMA-IR, and leptin concentrations and
an increased A/L ratio, an emerging novel marker of
IR. Changes in glucose, IGF1, IGFBP3, and adipo-
nectin were not observed. This trial has provided
Table 1 Baseline characteristics of participants, Alberta physical
activity,andBreast CancerPreventionTrial2003–2006,nZ320
a
Baseline
characteristic
Exercisers
(nZ160)
Controls
(nZ160)
MeanGS.D. MeanGS.D.
Age (years) 61.2G5.4 60.6G5.7
Body composition measurements
Body mass index (kg/m
2) 29.1G4.5 29.2G4.3
Intra-abdominal fat area (cm
2) 101.4G55.4 103.2G56.0
Total body fat (kg) 30.9G8.2 31.3G8.6
Percent body fat 42.2G4.9 42.4G5.7
N (%) N (%)
Education (Ohigh school) 112 (70) 102 (64)
White race/ethnicity 144 (91) 145 (91)
Median(IQR) Median (IQR)
Insulin (mIU/ml) 6.2 (3.8–9.5) 5.7 (3.4–8.9)
Glucose (mM) 5.4 (4.9–6.1) 5.3 (4.9–5.8)
HOMA-IR 1.4 (0.9–2.4) 1.4 (0.8–2.3)
IGF1 (ng/ml) 117 (95–138) 119 (100–141)
IGFBP3 (mg/ml) 4.0 (3.5–4.5) 3.9 (3.4–4.5)
Leptin (ng/ml) 19.2 (13.5–25.6) 20.9 (12.8–30.1)
Adiponectin (mg/ml) 11.5 (9.1–17.2) 12.5 (9.6–16.1)
Adiponectin/leptin 0.63 (0.38–1.07) 0.64 (0.37–1.09)
IGF1/IGFBP3 29.5 (25.9–33.6) 30.5 (25.9–40.0)
IQR, interquartile range; HOMA-IR, homeostasis model
assessment of insulin resistanceZfasting glucose (mM)!
fasting insulin (mIU/ml)/22.5; IGF1, insulin-like growth factor 1;
IGFBP3, insulin-like growth factor-binding protein 3.
aThere were no statistically signiﬁcant differences at baseline
between exercisers and controls for these variables.
Endocrine-Related Cancer (2011) 18 357–369
www.endocrinology-journals.org 361new and strong evidence for the role of these
biomarkers in the association between physical activity
and breast cancer risk that supports preliminary
ﬁndings from previous studies and expands that
research to other biomarkers.
Only a few large RCTs have examined the effects of
a long-term exercise-only intervention on these
metabolic factors in older women. Of ﬁve previous
noteworthy RCTs with similar study populations
and/or outcomes of interest (Houmard et al. 2004,
Frank et al. 2005, Giannopoulou et al. 2005, Pi-Sunyer
et al. 2007, Arsenault et al. 2009), only one trial lead
by McTiernan (Frank et al. 2005, McTiernan et al.
2005) was of comparable size, duration and scope to
the ALPHA Trial. In contrast to the other trials, the
ALPHA Trial included healthy, postmenopausal
women with a BMI ranging from 22–40kg/m
2 rather
than women with a BMI O25kg/m
2. Consequently,
these results are more generalizable to the population
at risk for postmenopausal breast cancer. The ALPHA
Trial also had several other study design features that
distinguish it from earlier RCTs, including the largest
sample size of healthy women, the most tightly
controlled exercise intervention that was supervised
for the entire 12-month period, a minimal loss to
follow-up, and the novel combination of biomarkers
that were examined. In particular, no previous RCT has
examined the effect of exercise on the ratio of
adiponectin/leptin. Since this ratio appears to estimate
IR (Finucane et al.2009), it was only recently proposed
as a biomarker of breast cancer risk (Cleary et al. 2009,
Jarde et al. 2009). Thus, our study provides a new
insight, using a potentially stronger indicator of breast
cancer risk than leptin or adiponectin on its own, into
how exercise impacts the causal pathway between
exercise and postmenopausal breast cancer.
Table 2 Difference between exercisers and controls on concentrations of proposed biomarkers over 6 and 12 months from baseline
Baseline 6 months 12 months
Treatment effect
ratio of exercise/
control (95% CI)
a
Between-
group
P value
Geometric mean
(95% CI)*
Geometric mean
(95% CI)
Geometric mean
(95% CI)
Insulin (mIU/ml)
Exercisers
b 6.1 (5.5 to 6.8) 5.4 (4.8 to 5.9) 5.3 (4.8 to 5.9) 0.87 (0.81 to 0.93) !0.001
Controls
c 5.7 (5.2 to 6.3) 6.0 (5.4 to 6.7) 5.9 (5.3 to 6.6)
Glucose (mM)
Exercisers 5.5 (5.4 to 5.7) 5.5 (5.3 to 5.7) 5.5 (5.3 to 5.6) 0.99 (0.97 to 1.02) 0.581
Controls 5.5 (5.3 to 5.6) 5.5 (5.4 to 5.7) 5.5 (5.3 to 5.6)
HOMA-IR
Exercisers 1.5 (1.3 to 1.7) 1.3 (1.2 to 1.5) 1.3 (1.1 to 1.4) 0.86 (0.80 to 0.93) !0.001
Controls 1.4 (1.2 to 1.5) 1.5 (1.3 to 1.6) 1.4 (1.3 to 1.6)
IGF1 (ng/ml)
Exercisers 117 (112 to 123) 114 (109 to 119) 115 (110 to 121) 1.00 (0.98 to 1.02) 0.995
Controls 120 (114 to 126) 116 (110 to 122) 116 (111 to 122)
IGFBP3 (mg/ml)
Exercisers 3.9 (3.8 to 4.0) 3.8 (3.7 to 4.0) 3.8 (3.7 to 3.9) 0.99 (0.97 to 1.00) 0.163
Controls 3.9 (3.8 to 4.0) 3.9 (3.7 to 4.0) 3.9 (3.7 to 4.0)
IGF1/IGFBP3
Exercisers 29.9 (28.9 to 31.0) 29.6 (28.6 to 30.6) 30.1 (29.1 to 31.2) 1.01 (0.99 to 1.03) 0.377
Controls 30.6 (29.3 to 31.9) 29.9 (28.7 to 31.2) 30.1 (28.9 to 31.3)
Leptin (ng/ml)
Exercisers 18.8 (17.3 to 20.4) 14.8 (13.5 to 16.2) 14.9 (13.5 to 16.5) 0.82 (0.78 to 0.87) !0.001
Controls 19.5 (17.7 to 21.4) 18.5 (16.7 to 20.4) 19.1 (17.4 to 21.1)
Adiponectin (mg/ml)
Exercisers 11.8 (10.9 to 12.9) 11.7 (10.7 to 12.7) 12.2 (11.3 to 13.3) 0.99 (0.97 to 1.02) 0.680
Controls 12.2 (11.4 to 13.1) 12.3 (11.4 to 13.2) 12.2 (11.4 to 13.1)
Adiponectin/leptin
Exercisers 0.63 (0.56 to 0.71) 0.79 (0.69 to 0.90) 0.82 (0.71 to 0.94) 1.21 (1.13 to 1.28) !0.001
Controls 0.63 (0.56 to 0.71) 0.67 (0.59 to 0.75) 0.64 (0.56 to 0.72)
CI, conﬁdence interval; HOMA-IR, homeostasis model assessment of insulin resistance; IGF1, insulin-like growth factor 1; IGFBP3,
IGF-binding protein 3.
aThe treatment effect ratio was calculated from a general linear model for each biomarker outcome, estimating a parameter whose
anti-logarithm corresponds to the ratio of adjusted geometric means of the biomarker for the exercise intervention group over the
control group: this ratio was assumed to be common at 6 and 12 months post-randomization.
bExercise group: n, baselineZ160, 6 monthZ154, 12 monthZ154.
cControl group: n, baselineZ160, 6 monthZ154, 12 monthZ156.
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study demonstrated decreased insulin concentrations
and HOMA-IR in exercisers that differed signiﬁcantly
from changes in controls across 12 months of exercise;
no signiﬁcant change in glucose was found in either
trial. Exercise also lowered circulating insulin
signiﬁcantly in the Dose–Response to Exercise in
Postmenopausal Women (DREW) trial, a 6-month
exercise RCT in 349 overweight/obese postmenopau-
sal women with elevated blood pressure; glucose levels
also decreased signiﬁcantly (Arsenault et al. 2009).
In general, exercise with moderate weight loss has
been found to improve insulin sensitivity (Albright
et al. 2000, Ryan 2000, Wareham et al. 2005) and
prevent type 2 diabetes (Gill & Cooper 2008, Physical
Activity Guidelines Advisory Committee 2008).
The impact of our intervention on breast cancer
prevention has not been tested. However, varying
insulin levels, comparable with the 12-month changes
that we observed in exercisers (6.1 vs 5.3 mIU/ml),
have signiﬁcantly altered breast cancer risk in
non-diabetic, postmenopausal women not using
hormone therapy (Gunter et al. 2009). In a large
etiologic study (Gunter et al. 2009), women with
insulin levels 3.9 to !5.6 mIU/ml experienced a
41% lower risk of breast cancer than women with 5.6
to !8.8 mIU/ml insulin (midpoints of the ranges
differed by 51%). Extrapolating those ﬁndings to our
study, assuming a linear relation between insulin and
breast cancer risk, we postulate that the 10% decrease
in insulin experienced by our exercise group would
lower breast cancer risk by w8%.
It remains unclear what exercise dose is optimal for
improving insulin sensitivity. In secondary analyses,
we observed signiﬁcant trends between exercise
adherence and insulin and HOMA-IR changes respec-
tively. Another RCT, the Studies of Targeted Risk
Reduction Interventions through Deﬁned Exercise
(STRRIDE), found improvements in insulin sensitivity
in 154 overweight/obese adults that were greater with
170 min/week of exercise than with 115 min/week,
supporting our ﬁnding of dose–response trends for
insulin and HOMA-IR when exercise exceeded
150 min/week (Houmard et al.2 0 0 4 ). In another
comparable trial (Frank et al. 2005), there was no
beneﬁt from exercising !130 min/week, but decreases
Table 3 Concentrations of proposed biomarkers at baseline and 12 months in controls and exercisers by three adherence levels
Baseline 12 months
Ratio 12 months/
baseline (95% CI)
a
Percent
change
b P value
c
P for
trend
d
Geometric mean
(95% CI)
Geometric mean
(95% CI)
Insulin (mIU/ml)
Controls
e 5.6 (5.1 to 6.2) 5.9 (5.3 to 6.6) 1.05 (0.98 to 1.13) 5.4 Ref !0.001
!150 min/week
e 7.4 (5.9 to 9.3) 7.1 (5.8 to 8.7) 0.96 (0.81 to 1.13) K4.4 0.679
150–225 min/week
e 5.6 (4.8 to 6.6) 4.9 (4.2 to 5.7) 0.87 (0.79 to 0.96) K13.1 0.002
O225 min/week
e 5.3 (4.4 to 6.4) 4.7 (4.0 to 5.6) 0.89 (0.79 to 0.99) K11.2 0.010
HOMA-IR
Controls 1.4 (1.2 to 1.5) 1.4 (1.3 to 1.6) 1.05 (0.97 to 1.13) 4.8 Ref !0.001
!150 min/week 1.9 (1.4 to 2.4) 1.8 (1.4 to 2.3) 0.97 (0.81 to 1.16) K3.4 0.860
150–225 min/week 1.3 (1.1 to 1.6) 1.2 (1.0 to 1.4) 0.87 (0.78 to 0.97) K12.8 0.007
O225 min/week 1.3 (1.0 to 1.6) 1.1 (0.9 to 1.3) 0.84 (0.75 to 0.95) K16.0 0.002
Leptin (ng/ml)
Controls 19.3 (17.5 to 21.2) 19.1 (17.4 to 21.1) 0.99 (0.94 to 1.05) K0.7 Ref !0.001
!150 min/week 18.0 (15.4 to 20.9) 17.3 (14.5 to 20.7) 0.96 (0.87 to 1.07) K3.6 0.513
150–225 min/week 19.9 (17.5 to 22.7) 16.1 (13.8 to 18.7) 0.81 (0.74 to 0.88) K19.2 !0.001
O225 min/week 16.8 (14.4 to 19.6) 11.8 (9.8 to 14.3) 0.70 (0.61 to 0.81) K29.6 !0.001
Adiponectin/leptin
Controls 0.64 (0.56 to 0.72) 0.64 (0.56 to 0.72) 1.00 (0.94 to 1.07) 0.2 Ref !0.001
!150 min/week 0.66 (0.51 to 0.86) 0.70 (0.52 to 0.94) 1.06 (0.94 to 1.20) 6.2 0.378
150–225 min/week 0.63 (0.54 to 0.75) 0.77 (0.64 to 0.94) 1.22 (1.11 to 1.34) 21.9 0.001
O225 min/week 0.68 (0.55 to 0.86) 1.02 (0.78 to 1.33) 1.48 (1.29 to 1.71) 48.4 !0.001
CI, conﬁdence interval; HOMA-IR, homeostasis model assessment of insulin resistance.
aRatio of geometric means at 12 months to geometric means at baseline.
bPercent change in proposed biomarker at 12 months from baseline for that level or group.
cP valuesfor changein proposed biomarkerat 12 months frombaseline betweencontrols and that level of exercise adherencegroup
adjusted for the baseline value.
dTest for trend in change in proposed biomarker at 12 months from baseline cross controls and three adherence groups adjusted for
the baseline value.
eNZ156, 40, 67, and 47 for controls and three exercise adherence levels %150, 150–225, O225 min/week, respectively.
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durations of 131 to 190 min/week; smaller decreases
occurred when duration exceeded 190 min/week.
Our ﬁndings for an effect of aerobic exercise on
insulin and HOMA-IR scores, which was attenuated
but not wholly explained by changes in adiposity, are
biologically plausible. Exercise may lower serum
insulin levels by promoting fat loss and preserving
lean body mass, and independently of fat loss by
increasing the number and activity of glucose
transporters in muscle and adipose tissue (Ryan
2000). Another trial of older women (Frank et al.
2005) found decreased insulin and HOMA-IR scores
only in women whose total body fat was decreased by
the intervention, which suggests these changes were
driven by fat loss. We similarly showed total and
percent body fat loss to be mediators of exercise-
induced changes in HOMA-IR (Table 4). The same
trial (Frank et al. 2005)s h o w e dn od i f f e r e n c e
across changes in body weight, percent body fat
or intra-abdominal adiposity, concordant with our
ﬁndings for insulin.
Early epidemiological evidence (Orenstein &
Friedenreich 2004) does not support an inverse
association between chronic exercise and circulating
levels of IGF1 and IGFBP3, particularly in older
women. This evidence is consistent with our ﬁndings
and other comparable RCTs (McTiernan et al. 2005,
Seo et al. 2010) with one exception: that RCT (Orsatti
et al. 2008) showed signiﬁcantly increased IGF1 with
exercise. A recent review also suggested that long-
term exercise may actually increase circulating IGF1
(Nindl & Pierce 2010). Therefore, the evidence is
weak that chronic exercise lowers IGF1 in postmeno-
pausal women.
Given that leptin and adiponectin derive almost
exclusively from adipose tissue, their levels should
change with exercise-induced body fat loss and
decreased central adiposity (Ritland et al.2 0 0 8 ),
which was experienced in this trial (Friedenreich
et al. 2010b). We observed reductions in leptin for
exercisers, which increased in a dose-dependent
manner with exercise adherence. Only a few studies
have addressed the effects of exercise on leptin in
postmenopausal women (Kohrt et al. 1996, Ryan et al.
2000, Hayase et al. 2002, Frank et al.2 0 0 5 ,
Giannopoulou et al.2 0 0 5 ) and only two of them were
RCTs (Frank et al. 2005, Giannopoulou et al. 2005).
Table 4 Treatment effect ratios for changes in proposed biomarkers over 6 and 12 months from baseline, before and after
adjustment for adiposity change
Treatment effect ratio of
exercise/control (95% CI)
a P value
Insulin (mIU/ml)
No adjustment 0.87 (0.81 to 0.93) !0.001
Adjustment for weight change 0.90 (0.84 to 0.96) 0.002
Adjustment for % body fat change 0.92 (0.86 to 0.99) 0.021
Adjustment for total body fat change 0.92 (0.86 to 0.99) 0.021
Adjustment for intra-abdominal fat area change 0.91 (0.85 to 0.98) 0.011
HOMA-IR
No adjustment 0.86 (0.80 to 0.93) !0.001
Adjustment for weight change 0.91 (0.84 to 0.98) 0.009
Adjustment for % body fat change 0.93 (0.87 to 1.01) 0.073
Adjustment for total body fat change 0.93 (0.87 to 1.00) 0.065
Adjustment for intra-abdominal fat area change 0.92 (0.85 to 0.99) 0.027
Leptin (ng/ml)
No adjustment 0.82 (0.78 to 0.87) !0.001
Adjustment for weight change 0.91 (0.87 to 0.95) !0.001
Adjustment for % body fat change 0.95 (0.90 to 0.99) 0.023
Adjustment for total body fat change 0.94 (0.90 to 0.99) 0.018
Adjustment for intra-abdominal fat area change 0.89 (0.85 to 0.95) !0.001
Adiponectin/leptin
No adjustment 1.21 (1.13 to 1.28) !0.001
Adjustment for weight change 1.08 (1.03 to 1.14) 0.004
Adjustment for % body fat change 1.04 (0.98 to 1.09) 0.207
Adjustment for total body fat change 1.03 (0.98 to 1.09) 0.207
Adjustment for intra-abdominal fat area change 1.10 (1.03 to 1.17) 0.003
CI, conﬁdence interval; HOMA-IR, homeostasis model assessment of insulin resistance.
aThe geometric mean ratios were estimated from least square means for the difference in treatment effect between exercisers and
controls averaged across the entire study period adjusted for the baseline values, and then back log-transformed.
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concentrations with exercise; however, in our most
adherent subgroup, we observed more than twice the
decrease in leptin (12% with O190 min/week (Frank
et al. 2005) versus 30% with O225 min/week). In
another RCT (Giannopoulou et al.2 0 0 5 ), leptin
decreased in exercisers, but the change was of
borderline statistical signiﬁcance (PZ0.06); this
difference might be attributable to the higher volume
of exercise undertaken in our trial or the minimal fat
loss in the earlier study. Adiponectin levels have an
inverse association with adiposity. Exercise may lower
the levels of the obesity-related inﬂammatory markers,
tumor necrosis factor-a, and interleukin 6, thereby
increasing adiponectin gene expression and secretion
(Bruun et al. 2003). However, we and others found
no changes in adiponectin levels with exercise
(Giannopoulou et al. 2005, Arsenault et al. 2009,
Coker et al. 2009, Ligibel et al. 2009). Although RCT
evidence relating chronic exercise to circulating
adiponectin has been inconclusive (Simpson & Singh
2008), it is hypothesized that levels increase with
sufﬁcient weight loss (Kraemer & Castracane 2007,
Christiansen et al. 2010), perhaps more than the 2.3 kg
weight loss in our trial (Friedenreich et al. 2010b) and
the others (Giannopoulou et al. 2005, Arsenault et al.
2009). We observed signiﬁcantly greater increases in
the A/L ratio in exercisers than in controls, driven
mainly by decreased leptin. This ﬁnding indicates
improved insulin sensitivity, as did the changes we
observed for insulin and HOMA-IR; all three indices
have been strongly associated with the insulin
sensitivity index from hyperinsulinaemic–euglycaemic
clamp studies (Finucane et al. 2009). Our secondary
analysis suggests that total and percent body fat loss
inﬂuenced the effect of exercise on the A/L ratio.
Our study’s strengths include its large size, long
duration, low drop-out rate, excellent adherence,
reliable assays, and quantitative assessments of total
and central adiposity. We studied the isolated effects of
exercise by not intervening on diet and this RCT was
the ﬁrst to investigate sustained exercise-induced
changes in the A/L ratio in older women. Limitations
include some lack of compliance among the control
group: 10% of controls increased recreational activity
by 20 MET-hours/week. We used insulin and HOMA-
IR as IR indicators, which are practical alternatives to
the gold standard euglycaemic hyperinsulinemic clamp
method (DeFronzo et al. 1979, Bergman et al. 1985).
Furthermore, given the number of secondary analyses
of these data, type I error is a possibility. In terms of
generalizability, our ﬁndings describe non-diabetic,
primarily Caucasian, normal weight to overweight and
obese postmenopausal women who were inactive at
baseline and, on average, had elevated leptin levels
relative to normal weight women.
Conclusion
This RCT demonstrated that signiﬁcant improvements
in IR indicators, leptin, and A/L proﬁles can be
achieved with sustained, moderate-to-vigorous aerobic
exercise in previously inactive, postmenopausal
women. Secondary analyses suggested that a decrease
in total or percent body fat may be required to alter
HOMA-IR and the A/L ratio. Similar to others, we
observed no effect of long-term exercise on IGF1 or
IGFBP3 levels. The beneﬁts of improved insulin
sensitivity include not only cancer risk reduction but
also lower risk of metabolic syndrome, cardiovascular
disease, and type 2 diabetes. Our ﬁnding of improved
hormone levels with exercise R150 min/week is
consistent with public health guidelines for prevention
of all-cause mortality, cardiovascular disease, and type
2 diabetes (Physical Activity Guidelines Advisory
Committee 2008) and lower than cancer prevention
recommendations (World Cancer Research Fund and
the American Institute for Cancer Research 2007), but
because the ALPHA Trial was not designed to answer
the question of exercise dose, further RCT evidence is
needed to conﬁrm our ﬁndings.
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